Recursion Pharmaceuticals, Inc. (RXRX) vs Trevi Therapeutics, Inc. (TRVI)
Recursion Pharmaceuticals, Inc. and Trevi Therapeutics, Inc. are both Biotechnology companies. Recursion Pharmaceuticals, Inc. and Trevi Therapeutics, Inc. are of similar size ($2.1B and $2.1B). Trevi Therapeutics, Inc. has the higher net margin (0.00% vs −945.9%) and the lower return on invested capital (−1,412.1% vs −92.2%). Across the 14 metrics below, Trevi Therapeutics, Inc. leads on 10 and Recursion Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | RXRX | TRVI | Biotechnology median |
|---|---|---|---|
| Gross margin | 3.48% | 0.00% | 65.16% |
| Operating margin | (991.72%) | 0.00% | 0.00% |
| Net margin | (945.92%) | 0.00% | 0.00% |
| Free cash flow margin | (645.82%) | 0.00% | 0.00% |
| Return on equity | (56.58%) | (19.66%) | (57.72%) |
| Return on assets | (41.26%) | (18.97%) | (49.22%) |
| Return on invested capital | (92.22%) | (1,412.11%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack